Filter Results:
(7)
Show Results For
- All HBS Web (7)
- Faculty Publications (5)
Show Results For
- All HBS Web (7)
- Faculty Publications (5)
Page 1 of 7
Results
- Profile
Ron Laufer
- January 2014
- Teaching Plan
MedImmune Ventures
By: Richard Hamermesh and Andrew Otazo
"MedImmune Ventures" highlights the problems faced by corporate venture capital firms, the challenges of investing in early-stage healthcare, and the difficulty of operating in distant markets. View Details
Keywords: MedImmune Ventures; NeuProtect; Corporate Venture Capital; Ron Laufer; Australia; Starfish Ventures; AstraZeneca; MEVE; Healthcare; Startup; Venture Capital; Business Startups; Health Industry; Australia; United States
Hamermesh, Richard, and Andrew Otazo. "MedImmune Ventures." Harvard Business School Teaching Plan 814-039, January 2014.
- August 2013 (Revised October 2013)
- Case
MedImmune Ventures
By: Richard G. Hamermesh and David Lane
Ron Laufer is the new Senior Managing Director of MedImmune Ventures, the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer... View Details
Keywords: MedImmune; MedImmune Ventures; AstraZeneca; NeuProtect; Corporate Venturing; Biotechnology; Venture Investing; Venture Capital; Health Care and Treatment; Pharmaceutical Industry; Financial Services Industry; Biotechnology Industry; United States; Australia; Europe; London
Hamermesh, Richard G., and David Lane. "MedImmune Ventures." Harvard Business School Case 814-023, August 2013. (Revised October 2013.)
- March 2010 (Revised April 2014)
- Case
American Well: The Doctor Will E-See You Now
By: Elie Ofek and Ron Laufer
What is next for healthcare IT provider American Well, whose innovative Online Care technology allows physicians to deliver care to patients online in real time? Using American Well's platform, patients with non-emergency health concerns can communicate with physicians... View Details
Keywords: Entrepreneurship; Health Care and Treatment; Technological Innovation; Growth and Development Strategy; Market Entry and Exit; Service Delivery; Online Technology; Health Industry
Ofek, Elie, and Ron Laufer. "American Well: The Doctor Will E-See You Now." Harvard Business School Case 510-061, March 2010. (Revised April 2014.)
- November 2006 (Revised July 2008)
- Case
Eli Lilly: Developing Cymbalta
By: Elie Ofek and Ron Laufer
Anticipating the expiration of its Prozac patent, Eli Lilly has to make tough decisions regarding the development of its next-generation antidepressant drug. In particular, the company needs to decide whether to first establish that once-a-day dosing for Cymbalta... View Details
Keywords: Decision Choices and Conditions; Marketing Strategy; Product Launch; Product Development; Research and Development; Pharmaceutical Industry
Ofek, Elie, and Ron Laufer. "Eli Lilly: Developing Cymbalta." Harvard Business School Case 507-044, November 2006. (Revised July 2008.)
- 09 Apr 2019
- News
Finding a Fix for Food Allergies
they found not only a network of support and resources, but also many classmates with their own family’s challenges with food allergies. The group includes Ron Laufer (MBA 2000),who conducted scientific... View Details
Keywords: Jill Radsken
- February 2006 (Revised July 2007)
- Case
Corporate Venture Capital at Eli Lilly
By: Richard G. Hamermesh, Ron Laufer and David Lane
Reviews the role of corporate venture capital and its history at Eli Lilly. Also presents a challenging venture investment opportunity. View Details
Hamermesh, Richard G., Ron Laufer, and David Lane. "Corporate Venture Capital at Eli Lilly." Harvard Business School Case 806-092, February 2006. (Revised July 2007.)